Table 2. Multivariate analysis of clinicopathological factors for PFS and OS in patients with WHO II and III diffuse gliomas who received adjuvant therapies (Group A, n = 246) and those who did not (Group B, n = 49) after surgery.
| Adjuvant therapies | Variables | PFS | OS | ||
|---|---|---|---|---|---|
| HR(95%CI) | p-value | HR(95%CI) | p-value | ||
| RT and/or CHT | Age | 1.016(1.000–1.033) | 0.054 | 1.020(1.002–1.039) | 0.031 |
| WHO grade (Grade II vs III) | 2.263(1.474–3.475) | <0.001 | 2.573(1.610–4.110) | <0.001 | |
| Complete resection (Yes vs. No) | 2.645(1.794–3.899) | <0.001 | 2.116(1.389–3.223) | <0.001 | |
| IDH mutation (Yes vs. No) | 2.424(1.524–3.854) | <0.001 | 2.652(1.632–4.308) | <0.001 | |
| 1p/19q codeletion (Yes vs. No) | 1.736(0.996–3.027) | 0.052 | 1.834(0.978–3.439) | 0.059 | |
| TERT promoter mutation(Yes vs. No) | 1.043(0.659–1.650) | 0.858 | 1.128(0.690–1.844) | 0.632 | |
| No RT or CHT | Age | 1.038(1.009–1.069) | 0.011 | 1.037(1.004–1.070) | 0.026 |
| WHO grade (Grade II vs III) | 11.330(3.770–34.048) | <0.001 | 7.001(2.167–22.615) | 0.001 | |
| Complete resection (Yes vs. No) | 1.528(0.665–3.508) | 0.318 | 1.705(0.747–3.892) | 0.205 | |
| IDH mutation (Yes vs. No) | 0.707(0.295–1.694) | 0.436 | 0.751(0.314–1.795) | 0.519 | |
| 1p/19q codeletion (Yes vs. No) | 0.936(0.302–2.898) | 0.908 | 1.738(0.510–5.923) | 0.377 | |
| TERT promoter mutation(Yes vs. No) | 1.832(0.704–4.765) | 0.215 | 1.665(0.635–4.366) | 0.300 | |
p values in bold were considered statistically significant
HR: hazard ratio; CI: confidence interval; RT: radiation therapy; CHT: chemotherapy.